I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...

BTX-A51 is a first-in-class, small molecule kinase inhibitor that co-targets casein kinase 1 alpha (CK1α and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), three master regulators of cancer ...

a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia. The company reported 67 percent overall response rate in target population, while the targeted response was 20 ...

Preclinical data suggest that SLS009, a highly selective CDK9 inhibitor, can induce apoptosis downstream of p53 by targeting critical proteins such as MCL-1 and survivin, regardless of p53 status.

The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to ...